Reading TBRG? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TBRG free→Reading TBRG? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TBRG free→NASDAQHealth CareHealth Information ServicesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. Management's recent track record has been fairly steady, but risk is elevated, and the sector backdrop is a headwind. Peer multiples imply a price about 33% above where it trades (it looks cheap on this basis); the read is cheap, quality intact. The outlook hinges on guidance from TBRG and the performance of sector bellwethers like VEEV, BTSG, and TEM. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 5 valuation methods, at three horizons. Current price $26.12. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $26 TBRG trades at 9× p/e, below its 15× p/e peer median. Our $40 fair value sits above the price; low confidence. Analysts: $26–$26. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 35% below a flat-multiple fair value, below our forecast of about 0%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 10.60x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.54 → $0.68 (+26.4% / 30d). 3 raised, 1 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d. 0% of analysts rate Buy.
Market and fundamentals agree. Analysts are positioned bullishly on a fundamentally strong name.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$50.
How much price usually moves either way.
On a bad day, this stock has moved -$384.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,073.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If revenue growth in the healthcare sector picks up, it could boost TruBridge's performance. This is crucial as the sector is maturing.
Confirms:Healthcare sector revenue growth is speeding up again. It is moving toward 10% or more.
Disproves:Healthcare sector revenue growth remains below 5%.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for TBRG yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 8, 2026, TruBridge, Inc. issued a press release announcing financial information for the first quarter ended March 31, 2026. The press release is attached as Exhibit 99.1 to this Form 8-K and is furnished to, but not filed with, the Securities and Exchange Commission.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$26.25 – $26.25 (median $26.25) · 3 analysts · as of 2026-04-27
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Technology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
TBRG TruBridge, Inc. | Above typical Show detailsSector percentile: 92 of 100 | inexpensive | elevated |
VEEV Veeva Systems | Above typical Show detailsSector percentile: 79 of 100 | full | elevated |
SOLV Solventum | Above typical Show detailsSector percentile: 75 of 100 | fair | moderate |
TEM TEMPUS AI, INC. | Above typical Show detailsSector percentile: 72 of 100 | — | elevated |
TXG 10X Genomics, Inc. | Typical Show detailsSector percentile: 47 of 100 | expensive | elevated |
10 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
TruBridge aims to grow by acquiring complementary businesses, as evidenced by the recent merger agreement.
TruBridge aims to maintain stable revenue levels as part of its operational focus.
TruBridge is focused on improving net income as part of its financial performance goals.
Why it matters: Earnings results will show if the company can maintain its recent momentum. Investors will look for revenue growth trends.
Confirms one read:Q2 earnings report shows revenue growth above 10% year over year.
Confirms the other:Q2 earnings report shows revenue growth below 5% year over year.
Entry into a Material Definitive Agreement. On April 23, 2026, TruBridge, Inc. (the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Inventurus Knowledge Solutions, Inc., a Delaware corporation (“ Parent ”), IKS Next Horizon, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“ Merger Sub ”), and solely for certain limited purposes as specified therein, Inventurus Knowledge Solutions Limited, an Indian public limit…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.” and which is available at https://www.sec.gov/ix?doc=/Archives/edgar/data/0001169445/000119312525115975/d848279d8k.htm . To the extent holdings of the Company’s securities by its directors or executive officers have changed since the amounts set forth in such 2025 proxy statement, such changes have been or will be reflected on Initial Statements o…
of this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as may be expressly set forth by specific reference in such filing. Cautionary Statement Regarding Forward-…
Results of Operations and Financial Condition. On March 31, 2026, TruBridge, Inc. issued a press release announcing financial information for the fourth quarter and year ended December 31, 2025. The press release is attached as Exhibit 99.1 to this Form 8-K and is furnished to, but not filed with, the Securities and Exchange Commission.